cimb-logo

Journal Browser

Journal Browser

Advances in Molecular Biology Methods in Hepatology Research, 2nd Edition

A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: 30 June 2026 | Viewed by 8066

Special Issue Editors


grade E-Mail Website
Guest Editor
Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, D-52074 Aachen, Germany
Interests: liver disease; fibrosis; biomarker; cytokines; chemokines; translational medicine
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, D-52074 Aachen, Germany
Interests: molecular biology; liver fibrosis; drug discovery and development; advanced in vitro models
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recent advances in molecular and cellular biology methods have had profound implications in deciphering the complexities of hepatology research. Specifically, these advancements are helping us to understand how the liver functions and how diseases develop. They are also allowing us to identify novel therapies and drugs and reduce drug toxicity. The integration of genomic technologies such as next-generation sequencing (NGS), single-cell sequencing, CRISPR-Cas9, and epigenetic studies allows for a more thorough analysis of the liver's genomic landscape. Similarly, progress in single-cell proteomic techniques, including sensitive mass spectrometry and high-throughput proteomics, has enabled the identification and quantification of liver proteins at the cellular level. These technologies help scientists comprehend the molecular pathways involved in liver injury, fibrosis, and regeneration. In addition to genomic techniques, the progress in hepatic in vivo models and liver tissue engineering, utilizing technologies such as CRISPR-Cas9, has aided in the creation of humanized organoid models. These technologies, such as hepatic organoids, are scalable for high-throughput screening and can replicate intricate cellular interactions, providing further insights into the mechanisms underlying liver diseases such as metabolic dysfunction-associated steatotic liver disease (MASLD), hepatitis, and liver fibrosis. By generating patient-derived organoids, researchers can personalize disease models, uncover individualized disease mechanisms, and develop efficient toxicity screening platforms and precision therapeutics. Overall, these advancements in molecular biology have propelled hepatology research to new heights, providing additional opportunities for efficient diagnosis, treatment, and prevention strategies for hepatic diseases.

You can read the publications in the first volume here: https://www.mdpi.com/journal/cimb/special_issues/4L8BQQE181.

Prof. Dr. Ralf Weiskirchen
Dr. Dileep G. Nair
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatic diseases
  • molecular biology methods
  • single-cell genomics
  • single-cell proteomics
  • hepatic organoids
  • biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

16 pages, 792 KB  
Review
Reconstructing Liver Fibrosis: 3D Human Models, Microbiome Interfaces, and Therapeutic Innovation
by Dileep G. Nair, Divya B. Nair and Ralf Weiskirchen
Curr. Issues Mol. Biol. 2026, 48(2), 165; https://doi.org/10.3390/cimb48020165 - 1 Feb 2026
Viewed by 2963
Abstract
Liver fibrosis is a significant consequence of severe liver injury resulting from viral hepatitis, alcohol, and metabolic dysfunction. Progressive fibrosis and ultimate cirrhosis are leading causes of morbidity and mortality worldwide, generally irreversible and poorly targeted by current therapies. Traditional in vitro models [...] Read more.
Liver fibrosis is a significant consequence of severe liver injury resulting from viral hepatitis, alcohol, and metabolic dysfunction. Progressive fibrosis and ultimate cirrhosis are leading causes of morbidity and mortality worldwide, generally irreversible and poorly targeted by current therapies. Traditional in vitro models and animal models mostly fail to fully recapitulate human multicellular crosstalk, extracellular matrix (ECM) remodeling, and the chronic, immune modulated nature of the disease. Recent advances in three-dimensional (3D) cell culture models including organoids, spheroids, bioprinted constructs, and organ-on-a-chip systems are advantageous for reconstructing cellular diversity and mechanical microenvironments to understand pathophysiology and aid in drug discovery. Emerging multi-organ models are capable of incorporating microbiome derived cues and using multi-omics readouts and imaging-enabled mechanistic dissection for more predictive anti-fibrotic screening. These technologies align well with the recent Modernization 3.0 regulation and New Approach Methodologies by the Food and Drug Administration (FDA) and recent EU Pharmaceutical Reform. This review summarizes the pathophysiology of liver fibrosis, the current landscape of 3D human liver models, and examines how microbiome interfaces modulate fibrogenesis. Full article
Show Figures

Figure 1

63 pages, 695 KB  
Review
Perfluoroalkyl Substances (PFAS) and Lipid Metabolism in Experimental Animal Models: A Scoping Review on the Mechanisms Behind the Induced Hepatotoxicity
by Gabriele Tancreda, Luca Campisi, Matteo Sarti, Luisa Pozzo and Andrea Vornoli
Curr. Issues Mol. Biol. 2025, 47(11), 944; https://doi.org/10.3390/cimb47110944 - 13 Nov 2025
Cited by 8 | Viewed by 2856
Abstract
Per and polyfluoroalkyl substances (PFAS) are a class of synthetic, persistent environmental pollutants detected in biological systems and increasingly recognized for their harmful effects on human health. The liver, being a central organ in the metabolism of xenobiotics, is profoundly affected by these [...] Read more.
Per and polyfluoroalkyl substances (PFAS) are a class of synthetic, persistent environmental pollutants detected in biological systems and increasingly recognized for their harmful effects on human health. The liver, being a central organ in the metabolism of xenobiotics, is profoundly affected by these compounds and is a main target of PFAS-induced toxicity. The purpose of the present Scoping Review is to investigate the multiple and complex mechanisms behind PFAS hepatotoxicity, taking into consideration evidence from preclinical in vivo models. Using electronic databases (PubMed and Google Scholar), a total of 38 studies were found eligible to be extensively explored to gather information regarding PFAS toxicity toward hepatic lipid metabolism, oxidative stress, injury and inflammation. Moreover, the parental exposure of these chemicals on the offspring will be discussed as well. As illustrated in the proposed graphical abstract, PFAS exposure has been linked to the triggering of oxidative stress phenomena, mitochondrial dysfunction and hepatic inflammatory infiltrate with sex specific effects in rodents. The predominant effects manifest as the overproduction of reactive oxygen species (ROS), the disruption of hepatic lipid metabolism, and the activation of several nuclear transcription factors involved in lipid regulation, with PPAR-α being the most prominent. Considering their strong bioaccumulative properties and persistence in both the environment and the human body, legacy and emerging PFAS should be regarded as potent toxicants with a distinctive role in the onset of metabolic diseases and as a pressing issue to be addressed within regulatory policies. Full article
Show Figures

Graphical abstract

23 pages, 839 KB  
Review
Advances in Multi-Omics Research on Biomarkers of Intrahepatic Cholangiocarcinoma
by Jingxue Yang, Jintong Na, Tieliu Shi and Xiyu Liu
Curr. Issues Mol. Biol. 2025, 47(11), 905; https://doi.org/10.3390/cimb47110905 - 31 Oct 2025
Cited by 1 | Viewed by 1768
Abstract
Intrahepatic cholangiocarcinoma (iCCA) is a rare yet aggressive malignancy characterized by late-stage diagnosis and poor prognosis. Recent advancements in multi-omics technologies have significantly enhanced the understanding of the molecular features and complex biological mechanisms of iCCA. These approaches have revealed disease molecular heterogeneity [...] Read more.
Intrahepatic cholangiocarcinoma (iCCA) is a rare yet aggressive malignancy characterized by late-stage diagnosis and poor prognosis. Recent advancements in multi-omics technologies have significantly enhanced the understanding of the molecular features and complex biological mechanisms of iCCA. These approaches have revealed disease molecular heterogeneity and identified biomarkers linked to disease progression, patient prognosis, and therapeutic outcomes. This review synthesizes findings from multi-omics studies, highlighting their clinical implications and advancing the application of precision oncology in iCCA management. Full article
Show Figures

Figure 1

Back to TopTop